Xiang, Q., Zhan, M., Li, Y., Liang, H., Hu, C., Huang, Y., . . . Lu, L. (2019). Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway. Taylor & Francis Group.
Chicago Style (17th ed.) CitationXiang, Qing-Feng, et al. Activation of MET Promotes Resistance to Sorafenib in Hepatocellular Carcinoma Cells via the AKT/ERK1/2-EGR1 Pathway. Taylor & Francis Group, 2019.
MLA (9th ed.) CitationXiang, Qing-Feng, et al. Activation of MET Promotes Resistance to Sorafenib in Hepatocellular Carcinoma Cells via the AKT/ERK1/2-EGR1 Pathway. Taylor & Francis Group, 2019.
Warning: These citations may not always be 100% accurate.